×

Biohaven's Verdiperstat Fails To Show Efficacy For Multiple System Atrophy Treatment; Stock Down

Published Sep 27 2021 at 12:09 PM GMT
Key
Points
  • (RTTNews) - Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy measure, nor on the key secondary efficacy measure, as per results from phase III trial in multiple system atrophy.
  • In Monday pre-market trade, BHVN was trading at $126.50, down $6.




Trending

Stats

  • Published Sep 27, 2021 12:09 PM GMT